Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 411 to 420 of 432 total matches.

Two New Drugs for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
and Skin Structure Infections The FDA has approved two new drugs for treatment of adults with acute ...
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ). Tedizolid phosphate (Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox). A third IV antibiotic, oritavancin (Orbactiv), recently approved by the FDA for the same indication, will be reviewed in a future...
Med Lett Drugs Ther. 2014 Aug 18;56(1449):73-5 |  Show IntroductionHide Introduction

IV Artesunate for Severe Malaria

   
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020  (Issue 1604)
. Treatment of malaria: guidelines for clinicians (United States). Available at: www.cdc.gov/malaria ...
Artesunate for injection (Amivas LLC), a semi-synthetic artemisinin derivative, is now approved by the FDA for initial (induction) treatment of severe malaria in children and adults. It has been available from the CDC on a compassionate use basis since 2007. Artemether/lumefantrine (Coartem), another artemisinin-based drug, was approved earlier for oral treatment of uncomplicated Plasmodium falciparum malaria. IV artesunate is now the only FDA-approved injectable antimalarial drug available in the US; IV quinidine has been discontinued.
Med Lett Drugs Ther. 2020 Aug 10;62(1604):121-4 |  Show IntroductionHide Introduction

Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010  (Issue 1333)
tabs. 1. Cost for 30 days' treatment at the lowest dosage, according to AWP listings of prescription ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Med Lett Drugs Ther. 2010 Mar 8;52(1333):17-9 |  Show IntroductionHide Introduction

Elbasvir/Grazoprevir (Zepatier) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016  (Issue 1489)
— elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment ...
The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.
Med Lett Drugs Ther. 2016 Feb 29;58(1489):25-7 |  Show IntroductionHide Introduction

Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community ...
Lefamulin (Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin (Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.
Med Lett Drugs Ther. 2019 Sep 23;61(1581):145-8 |  Show IntroductionHide Introduction

Lebrikizumab (Ebglyss) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated ...
The FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg). Lebrikizumab is the third subcutaneously injected human IgG4 monoclonal antibody to be approved in the US for this indication. Tralokinumab (Adbry), another IL-13 antagonist, is also approved for use in patients ≥12 years old, and dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81   doi:10.58347/tml.2024.1715b |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
infection. Annu Rev Med 2022; 73:183. 26. WD Chey et al. ACG clinical guideline: treatment of Helicobacter ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
or mid-range ejection fraction.1,2 HF WITH REDUCED EJECTION FRACTION STANDARD TREATMENT — All patients ...
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8   doi:10.58347/tml.2025.1729a |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
Opioids for Pain A new CDC guideline for prescribing opioids for pain recently became available.1 ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction